|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 471/04 | |
| A61K 31/4985 | |||
| A61P 25/28 |
| (11) | Number of the document | 3126361 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15714951.9 |
| Date of filing the European patent application | 2015-03-18 | |
| (97) | Date of publication of the European application | 2017-02-08 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2015/051988 |
| Date | 2015-03-18 |
| (87) | Number | WO 2015/150957 |
| Date | 2015-10-08 |
| (30) | Number | Date | Country code |
| 201461973436 P | 2014-04-01 | US |
| (72) |
AM ENDE, Christopher William, US
HUMPHREY, John Michael, US
JOHNSON, Douglas Scott, US
KAUFFMAN, Gregory Wayne, US
PETTERSSON, Martin Youngjin, US
RANKIC, Danica Antonia, US
STEPAN, Antonia Friederike, US
VERHOEST, Patrick Robert, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS |
| CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS |